舒泰神 (300204)
Staidson (Beijing) Biopharmaceuticals Co.,Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 47777.26
- Circulating A-Shares(W): 45366.45
- Earnings Per Share(RMB): -0.0600
- Net Assets Per Share(RMB): 1.8222
- Operating Revenue(W RMB): 18053.84
- Total Profit(W RMB): -3779.93
- Net Profit Attributable to Parent(W RMB): -3068.95
- Net Profit Growth Rate(%): -227.71
- Weighted Return on Equity(%): -3.4100
- Operating Cash Flow Per Share(RMB): -0.2240
- Undistributed Profit Per Share(RMB): -0.9407
- Capital Reserve Per Share(RMB): 1.1692
2. Main Business
The main business covers:
- Research, development, production, and marketing of biological drugs.
3. Company Basic Information
- Company Name: Staidson (Beijing) BioPharmaceuticals Co., Ltd.
- Listing Date: 2011-04-15
- Industry: Pharmaceutical Manufacturing
- Address: No. 36 Jinghai Second Road, Beijing Economic-Technological Development Area, Beijing, China
- Website: www.staidson.com
- Company Profile: The company's predecessor was Staidson (Beijing) Pharmaceutical Co., Ltd., established on August 16, 2002. In May 2009, Staidson (Beijing) Pharmaceutical Co., Ltd. was converted into a joint stock company by changing its registered capital to 46.50 million shares based on the audited net assets of RMB 66,550,068.67 as of April 30, 2009, with the remaining amount credited to capital reserve. Lixin Yonghua certified the registered capital at the time of establishment and issued the Capital Verification Report. On May 26, 2009, the company was registered with the Beijing Administration for Industry and Commerce and obtained the Business License.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Yizhao (Beijing) Pharmaceutical Technology Co., Ltd. | General Legal Person | 14816.60 | 32.66 |
| 2 | Xiangtang Group Co., Ltd. | General Legal Person | 2713.96 | 5.98 |
| 3 | Xingquan Herun Hybrid Securities Investment Fund (LOF) Class A | Fund | 1226.91 | 2.70 |
| 4 | Huatai Securities Asset Management - China Merchants Bank - Huatai Jili No.16 Collective Asset Management Plan | Asset Management Plan | 938.26 | 2.07 |
| 5 | Xingquan Heyi Flexible Allocation Hybrid Securities Investment Fund (LOF) Class A | Fund | 933.96 | 2.06 |
| 6 | Fullgoal Fund - China Life Insurance Company Limited - Traditional Insurance - Fullgoal Fund Guoshou Shares Growth Stock Traditional Available-for-sale Single Asset Management Plan | Asset Management Plan | 729.64 | 1.61 |
| 7 | E Fund Healthcare Industry Hybrid Securities Investment Fund Class A | Fund | 583.89 | 1.29 |
| 8 | Fullgoal Fund - China Life Insurance Company Limited - Participating Insurance - Fullgoal Fund Guoshou Shares Growth Stock Portfolio Single Asset Management Plan (Available-for-sale) | Asset Management Plan | 564.45 | 1.24 |
| 9 | E Fund Taihe Growth Equity Pension Product - Industrial and Commercial Bank of China Limited | Asset Management Plan | 434.31 | 0.96 |
| 10 | Great Wall Pharmaceutical Industry Selection Hybrid Initiated Securities Investment Fund Class A | Fund | 348.72 | 0.77 |
5. Concept Sectors
- Immunotherapy
- Assisted Reproduction
- Innovative Drugs
- High Price-to-Book Ratio
- Shareholder Reduction
- Private Placement Plan
- Consecutive Losses
- Equity Transfer
- Proposed Reduction
- Fund Reduction
- ChiNext 300
- ChiNext Healthcare
- ChiNext 200
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information